我是 LongbridgeAI，我可以總結文章信息。人工智能生物技術悖論：Moderna 與默克的第三階段黑色素瘤數據為人工智能輔助的個性化癌症疫苗提供了另一個驗證點。但投資者冒着將其視為軟件交易的風險，而生物學並不是軟件。人工智能可以在幾秒鐘內生成數千種生物設計，但實際合成、測試和驗證這些設計仍然可能需要數月時間
The AI Biotech Paradox
Moderna’s Phase 3 melanoma data with Merck provides another validation point for AI-assisted personalized cancer vaccines. But investors risk treating this like a software trade, and biology is not software.
AI can generate thousands of biological designs in seconds, but physically synthesizing, testing and validating them can still take months.